Focal amplification and activating point mutation of the MET gene are well-characterized
oncogenic drivers that confer susceptibility to targeted MET inhibitors. Recurrent somatic …

Black Americans are disproportionately affected by dementia. To expand our understanding
of mechanisms of this disparity, we look to Alzheimer's disease (AD) biomarkers. In this …

Although the BRAF V600E base substitution is an approved target for the BRAF inhibitors in
melanoma, BRAF gene fusions have not been investigated as anticancer drug targets. In our …

Background Pediatric brain tumors are the leading cause of death for children with cancer in
the US Incorporating next‐generation sequencing data for both pediatric low‐grade (pLGGs) …

Pancreatic acinar cell carcinomas (PACC) account for approximately 1%(∼ 500 cases) of
pancreatic cancer diagnoses annually in the United States. Oncogenic therapuetic targets …

A great deal is known about the effects of positive reinforcement on response acquisition; by
contrast, much less research has been conducted on contingencies applied to errors. We …

Abstract Background. The National Comprehensive Cancer Network (NCCN) guidelines for
patients with metastatic non-small cell lung cancer (NSCLC) recommend testing for EGFR …

Introduction MET proto-oncogene, receptor tyrosine kinase gene exon 14 skipping
(METex14) alterations represent a unique subset of oncogenic drivers in NSCLC …

A small fraction of cancer patients with advanced disease survive significantly longer than
patients with clinically comparable tumors. Molecular mechanisms for exceptional …

Purpose: We sought to identify genomic alterations (GA) in salivary gland adenocarcinomas,
not otherwise specified (NOS), salivary duct carcinomas (SDC), carcinoma ex pleomorphic …